nature portfolio

Corresponding author(s):	Aditi N Borkar
Last updated by author(s):	Apr 11, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				•
़ .	トつ	1	ıct	ICC
.)	ıd	ш	וכו	ics

For	all statistical a	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed	
	The exac	t sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
] 🔀 A statem	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statis	stical test(s) used AND whether they are one- or two-sided mon tests should be described solely by name; describe more complex techniques in the Methods section.
	A descrip	otion of all covariates tested
X	A descrip	otion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full des	scription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) ation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null h	hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted ues as exact values whenever suitable.
X	For Baye	sian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hiera	rchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimate:	s of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	1	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

OrbiSIMS spectra were acquired using IonToF SurfaceLab 7.2.128699

Data analysis

Custom scripts written for MATLAB 2021a were used to perform all the data analysis. These script files along with a comprehensive code documentation file that enlists the system requirements, installation instructions, step-by-step instructions for running the scripts and explanations of file formats and functionalities, and a sample dataset for users to test and understand the code's functionality are available on GitHub repository https://github.com/BorkarLab/OrbiSIMS_RNA_analysis/tree/RNA_published60 with DOI 10.5281/zenodo.10960751.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The raw cryo-OrbiSIMS data generated in this study is deposited in The University of Nottingham Collection of Public Research Data59 [http://doi.org/10.17639/

nott.7354] and can also be made available upon request from the corresponding author. All processed data supporting the findings of this study is provided within the main text and supplementary information. The following Protein Data Bank entries were used to benchmark the cryo-OrbiSIMS modelled 2D and 3D structures: (1) PDB ID 4ZT9 for Cas9:sg complex [https://doi.org/10.2210/pdb4ZT9/pdb], (2) PDB ID 6GWT [https://doi.org/10.2210/pdb6GWT/pdb] for bacterial ribosome complex, and (3) PDB IDs 5IEM [https://doi.org/10.2210/pdb5IEM/pdb], 5LYS [https://doi.org/10.2210/pdb5LYS/pdb], 5LYU [https://doi.org/10.2210/pdb5LYV/pdb], 6MCI [https://doi.org/10.2210/pdb6MCI/pdb], 6MCF [https://doi.org/10.2210/pdb6MCF/pdb], 6DCB [https://doi.org/10.2210/pdb6DCB/pdb], 6DCC [https://doi.org/10.2210/pdb6DCC/pdb], 2KX8 [https://doi.org/10.2210/pdb6DCB/pdb], 6D12 [https://doi.org/10.2210/pdb6D12/pdb], 7SLP [https://doi.org/10.2210/pdb7SLP/pdb] and 7SLQ [https://doi.org/10.2210/pdb7SLQ/pdb] for the 7SK RNP complex. Additionally, DMS probing dataset [https://doi.org/10.7554/eLife.22037] and IM7 probing dataset from RMDB 5SRRNA_IM7_0006 [https://rmdb.stanford.edu/detail/5SRRNA_1M7_0006] were used for performance comparison of cryo-OrbiSIMS with these techniques.

D 1	A CONTRACTOR OF THE PARTY OF TH	1	and the second second	and the second of the second	1.0		
Recearch	involving	hiiman	narticinant	s, their data	or biold	וסורם	material
NC3Cal CII	IIIVOIVIIIg	Hullian	participant	s, tricii data	, or block	zgicai	matthai

Policy information abo and sexual orientation		ith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation), hnicity and racism</u> .		
Reporting on sex and	on sex and gender The research doesn't involve human participants and thus this information has not been collected.			
Reporting on race, ethnicity, or other socially relevant groupings The research doesn't involve human participants and thus this information has not been collected.		The research doesn't involve human participants and thus this information has not been collected.		
Population character	tion characteristics The research doesn't involve human participants and thus this information has not been collected.			
Recruitment		The research doesn't involve human participants and thus this information has not been collected.		
Ethics oversight	Ethics oversight The research doesn't involve human participants and thus this information has not been collected.			
Note that full information	n on the appro	oval of the study protocol must also be provided in the manuscript.		
Field-spec	ific re	porting		
Please select the one b	below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	Ве	ehavioural & social sciences		
For a reference copy of the d	document with a	ll sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scienc	es stu	ıdy design		
All studies must disclo	se on these p	points even when the disclosure is negative.		
	Sample size is not applicable to this study as the mass spectrum generated via cryo-OrbiSIMS is dependent upon complex biochemical characteristics of the RNA system studied.			
Data exclusions No	No data was excluded from this study.			
		replicates were collected for each RNA system studied and under each sample preparation conditions (native, denaturing or ogical replicates were also collected for the 7SK RNP system. All replication attempts were successful.		
	Randomization is not applicable to this study as the mass spectrum collected for each RNA system is a unique fingerprint and is dependent upon the RNAs biochemical and structural characteristics.			
0	-	t relevant to this study because the source of each of the mass spectrum collected in the experiments was needed to be pownstream peak assignments and structure modeling.		

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experime	ntal systems Methods		
n/a Involved in the study	n/a Involved in the study		
Antibodies	ChIP-seq		
Eukaryotic cell lines	Flow cytometry		
Palaeontology and a	rchaeology MRI-based neuroimaging		
Animals and other o	[*] ganisms		
Clinical data			
Dual use research of	concern		
Plants			
Antibodies			
Antibodies used			
	Secondary antibodies: Anti mouse IgG (whole molecule) – HRP (produced in Goat) A4416 P code 1003321740, Source SLCK7186, Sigma Aldrich		
	Primary antibodies:		
	HEXIM1 Rabbit polyclonal IgG Catalog number 15676-1-AP, Lot number 00006924, Proteintech Genbank accession number: BC006460		
	Immunogen catalog number: Ag8144		
	Gene ID (NCBI): 10614		
	CDK9 Rabbit polyclonal IgG 11705-1-AP, Lot 00047991, Proteintech		
	Genbank accession number: BC001968 Immunogen catalog number: Ag2318		
	Gene ID (NCBI): 1025		
	Cyclin T1 Rabbit polyclonal IgG 20992-1-AP, Lot 00016402 Proteintech Genbank accession number:NM_001240		
	Gene ID (NCBI): 904		
	HSP90 13171-1-AP, Lot 00057547, Proteintech		
	Genbank accession number: BC023006 Gene ID (NCBI): 3320		
Validation	All primary antibodies were sourced from verified suppliers, and each primary antibody was validated for use by the manufacturer. Detailed information, including validation tests and link to publications, is available on the suppliers website, accessed via the following links.		
	HEXIM1 Rabbit polyclonal IgG: https://www.ptglab.com/products/HEXIM1-Antibody-15676-1-AP.htm		
	CDK9 Rabbit polyclonal IgG: https://www.ptglab.com/products/CDK9-Antibody-11705-1-AP.htm		
	Cyclin T1 Rabbit polyclonal IgG: https://www.ptglab.com/products/CCNT1-Antibody-20992-1-AP.htm		
	HSP90 Rabbit polyclonal IgG: https://www.ptglab.com/products/HSP90-Antibody-13171-1-AP.htm		
Eukaryotic cell line	es		
Policy information about <u>cell lines and Sex and Gender in Research</u>			
Cell line source(s)	Two batches of commercial HeLa cell lines donated by members of the author's institution were used in this study. Batch 1 was retrieved from passage no. 18, dated 12/09/12.		

Cell line source(s)	Two batches of commercial HeLa cell lines donated by members of the author's institution were used in this study. Batch 1 was retrieved from passage no. 18, dated 12/09/12. Batch 2 was donated on 01/10/2019
Authentication	None of the cell lines were authenticated
Mycoplasma contamination	Cell lines were not tested for mycoplasma contamination as this is not relevant to growing cells purely for protein extraction.
Commonly misidentified lines (See <u>ICLAC</u> register)	N/A

Plants

Seed stocks	n/a
Novel plant genotypes	n/a
, , , , , , , , , , , , , , , , , , ,	
Authentication	n/a